Answers are grounded in this paper and cite their sources.
Background: Pseudomonas aeruginosa infections in bronchiectasis airways result in poorer lung function, advanced lung lobe involvement, worsened life quality, and higher hospitalisation rates. Despite high prevalence, little is known about P. aeruginosa population genomics, antimicrobial resistance (AMR) rates, persistence, and transmission dynamics in Australians with bronchiectasis. Methods: P. aeruginosa (n=137) isolated between 2009 and 2025 from 59 Australians with bronchiectasis underwent antimicrobial susceptibility testing against 11 antipseudomonal drugs, whole-genome sequencing, comparative genomics, and in silico AMR determinant identification. Data were integrated with 4,575 publicly available bronchiectasis-derived P. aeruginosa genomes to determine global phylogenomic and AMR determinant patterns. Results: High AMR rates were identified in the Australian isolates, with 75.9% resistant to at least one antimicrobial, 19.7% multidrug-resistant, and 9.5% extremely drug-resistant. AMR rates were highest (64.2%) for ciprofloxacin and cefepime (44.5%), and lowest for piperacillin/tazobactam (8.8%) and colistin (0.7%). Phylogenomics uncovered several instances of within-host evolution, hypermutation, persistence, and multi-lineage infections. Of the fifty-seven identified multilocus sequence types (STs), seven (12.3%) were novel, five were high-risk international clones (ST274 [6.6%], ST395 [0.7%], ST244 [0.7%], ST277 [0.7%], ST298 [0.7%]) and three were common global clones (ST253 [5.1%], ST155 [3.6%], ST260 [0.7%]). No high-risk AMR-conferring mobile genetic elements were seen, although numerous chromosomal AMR determinants were identified. AMR determinant prevalence was consistent with the global dataset, with no evidence of geographic clustering. Conclusions: Our study provides critical insights into P. aeruginosa diversity in Australians with bronchiectasis. High AMR rates and chronic colonisation highlight the need to improve diagnostics, antimicrobial stewardship measures, and infection control practices in this neglected clinical cohort.
No takes yet. Share an insight, caveat, or question.
Strickland et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: